“As the world’s effort to introduce meaningful therapies for Alzheimer’s disease inches closer and closer to success, it is clear that the greatest benefit will come to those whose disease is detected at a very early stage,” said Jonathan L. Liss, MD, Director at Columbus Memory Center and Founder of Columbus Memory Project who has been studying Altoida’s technology since September 2018. “The Altoida technology offers an ingenious way in which to detect early disease and track progression without prolonged cognitive testing, tissue sampling, or radiologic intervention. The Altoida technology is a welcome advancement to the field of cognitive health.”